To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
64
Avacincaptad Pegol in combination with Lucentis
Avacincaptad Pegol in combination with Lucentis
Systemic Adverse Events
Number of Participants with systemic treatment-emergent Adverse Events (with calculated percentage)
Time frame: 6 months
Ophthalmic Adverse Events
Number of participants with ophthalmic Adverse Events (with calculated percentage)
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Retinal Research Institute
Phoenix, Arizona, United States
Retina Centers PC
Tucson, Arizona, United States
Retina Associates SW, PC
Tucson, Arizona, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Retina Consultants of Orange County
Fullerton, California, United States
Retina Consultants of Southern California
Redlands, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States
Orange County Retina Medical Group
Santa Ana, California, United States
Colorado Retina Associates
Golden, Colorado, United States
Florida Eye Clinic
Altamonte Springs, Florida, United States
...and 18 more locations